Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 27Prostatic Neoplasms 5Osteosarcoma 5Neuroendocrine Tumors 5Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Neoplasm Metastasis 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma, Ewing 3Sarcoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Penile Neoplasms 2Melanoma 2Lung Neoplasms 2Central Nervous System Neoplasms 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High Grade Neuroendocrine Neoplasms × cabozantinib × 90 days × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡